These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12000179)

  • 1. In vitro testing of platinum-based drugs on a panel of human ovarian tumour cell lines.
    Garner CM; Hubbold LM; Chakraborti PR
    Br J Biomed Sci; 2002; 59(1):15-9. PubMed ID: 12000179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
    Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
    Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.
    Kelland LR; Jones M; Abel G; Valenti M; Gwynne J; Harrap KR
    Cancer Chemother Pharmacol; 1992; 30(1):43-50. PubMed ID: 1586979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
    Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
    Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs.
    Harrap KR; Jones M; Siracky J; Pollard LA; Kelland LR
    Ann Oncol; 1990; 1(1):65-76. PubMed ID: 2078487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours.
    Sargent JM; Elgie AW; Williamson CJ; Taylor CG
    Br J Cancer; 1996 Dec; 74(11):1730-3. PubMed ID: 8956785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer.
    Sevin BU; Perras JP
    Am J Obstet Gynecol; 1997 Apr; 176(4):759-66; discussion 766-8. PubMed ID: 9125599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
    Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ
    Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
    Hills CA; Kelland LR; Abel G; Siracky J; Wilson AP; Harrap KR
    Br J Cancer; 1989 Apr; 59(4):527-34. PubMed ID: 2653399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
    Jones M; Siracky J; Kelland LR; Harrap KR
    Br J Cancer; 1993 Jan; 67(1):24-9. PubMed ID: 8427780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines.
    Groen HJ; Sleijfer S; Meijer C; Kampinga HH; Konings AW; De Vries EG; Mulder NH
    Br J Cancer; 1995 Dec; 72(6):1406-11. PubMed ID: 8519652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
    Perez RP; O'Dwyer PJ; Handel LM; Ozols RF; Hamilton TC
    Int J Cancer; 1991 May; 48(2):265-9. PubMed ID: 2019469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
    Rixe O; Ortuzar W; Alvarez M; Parker R; Reed E; Paull K; Fojo T
    Biochem Pharmacol; 1996 Dec; 52(12):1855-65. PubMed ID: 8951344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
    Sun X; Lou LG; Sui DH; Wu XH
    Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
    Sharp SY; Mistry P; Valenti MR; Bryant AP; Kelland LR
    Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
    Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
    Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.